CAS 74150-27-9
:Pimobendan
- (±)-Ud Cg 115Bs
- 2-(4-methoxyphenyl)-5(6)-(5-methyl-3-oxo-4,5-dihydro-2H-6-pyridazinyl)benzimidazole
- 3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-
- 3(2H)-pyridazinone, 4,5-dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-
- 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone
- 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone
- 6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one
- 6-[2-(4-Methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one
- Acardi
- Pimobenda
- Racemic pimobendan
- Ud Cg 115 Bs
- Ud-Cg 115
- Vetmedin
- Voir plus de synonymes
Pimobendan
CAS :PimobendanFormule :C19H18N4O2Degré de pureté :99.5%Couleur et forme :WhiteMasse moléculaire :334.14298PIMOBENDAN CRS
CAS :PIMOBENDAN CRSFormule :C19H18N4O2Couleur et forme :PowderMasse moléculaire :334.3718Pimobendan
CAS :Drugs with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoiFormule :C19H18N4O2Couleur et forme :White Yellow PowderMasse moléculaire :334.14298Pimobendan
CAS :Pimobendan (UD-CG 115 BS) is a selective inhibitor of PDE3 (IC50: 0.32 μM).Formule :C19H18N4O2Degré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :334.376-(2-(4-Methoxyphenyl)-1H-Benzo[D]Imidazol-5-Yl)-5-Methyl-4,5-Dihydropyridazin-3(2H)-One
CAS :6-(2-(4-Methoxyphenyl)-1H-Benzo[D]Imidazol-5-Yl)-5-Methyl-4,5-Dihydropyridazin-3(2H)-OneFormule :C19H18N4O2Degré de pureté :99%Couleur et forme : white to almost white crsytal to powderMasse moléculaire :334.37g/molPimobendan
CAS :Formule :C19H18N4O2Degré de pureté :>98.0%(T)(HPLC)Couleur et forme :White to Almost white powder to crystalMasse moléculaire :334.38Pimobendan 100 µg/mL in Acetonitrile
CAS :Formule :C19H18N4O2Couleur et forme :Single SolutionMasse moléculaire :334.37Pimobendan-d3
CAS :Produit contrôléApplications Pimobendan-d3, is the labeled analogue of Pimobendan (P447500), a cardiotonic agent.
References Yokota, S. et al.: Yakuri Chiryo, 20, 1143 (1992); Yamamoto, M. et al.: Kank. Igaku Ken. Nenpo, 47, 155 (1996); Matsumoto, A. et al.: Cardiovas. Drugs Ther., 12, 595 (1998);Formule :C19H15D3N4O2Couleur et forme :NeatMasse moléculaire :337.39rac Pimobendan
CAS :Produit contrôléApplications Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of Pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of Pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction.
References Yokota, S. et al.: Yakuri Chiryo, 20, 1143 (1992); Yamamoto, M. et al.: Kank. Igaku Ken. Nenpo, 47, 155 (1996); Matsumoto, A. et al.: Cardiovas. Drugs Ther., 12, 595 (1998);Formule :C19H18N4O2Couleur et forme :NeatMasse moléculaire :334.37Pimobendan
CAS :Pimobendan is a drug that has been shown to have positive effects on the cardiac function of experimental animals. It is a selective inhibitor of the enzyme phosphodiesterase 3 in cardiac tissues. Pimobendan also has effects on blood pressure, as it increases systolic pressure and decreases diastolic pressure. The pharmacokinetic properties of pimobendan are characterized by a concentration-time curve with a long terminal half-life. Pimobendan is also an ATP-sensitive K+ channel blocker, which causes increased intracellular K+ concentrations in the myocardium. This leads to an increase in cardiac contractility and relaxation, with an improvement in cardiac performance. Chronic oral administration of pimobendan has been shown to be effective in improving the long-term efficacy of treatment for congestive heart failure due to chronic valvular disease or dilated cardiomyopathy.Formule :C19H18N4O2Degré de pureté :Min. 95%Couleur et forme :White PowderMasse moléculaire :334.37 g/mol













